Cited 25 times in
Updated treatment strategies for intestinal Behcet's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용은 | - |
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2018-08-28T16:45:20Z | - |
dc.date.available | 2018-08-28T16:45:20Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161904 | - |
dc.description.abstract | Behcet's disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor alpha are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association of Internal Medicine | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Updated treatment strategies for intestinal Behcet's disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Yong Eun Park | - |
dc.contributor.googleauthor | Jae Hee Cheon | - |
dc.identifier.doi | 10.3904/kjim.2017.377 | - |
dc.contributor.localId | A04571 | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J02883 | - |
dc.identifier.eissn | 2005-6648 | - |
dc.identifier.pmid | 29207867 | - |
dc.subject.keyword | Adalimumab | - |
dc.subject.keyword | Biological products | - |
dc.subject.keyword | Infliximab | - |
dc.subject.keyword | Intestinal Behcet disease | - |
dc.subject.keyword | Tumor necrosis factor-alpha | - |
dc.contributor.alternativeName | Park, Yong Eun | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.affiliatedAuthor | Park, Yong Eun | - |
dc.contributor.affiliatedAuthor | Cheon, Jae Hee | - |
dc.citation.volume | 33 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 43119 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, Vol.33(1) : 43119, 2018 | - |
dc.identifier.rimsid | 59495 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.